


Advances in Oncology


Molecular profiling diagnosis or relapse



TYPICAL SENSITIVITY
5%-25%

NPM1	CEBPA
inv(16)	FLT3
AML1-ETO	IDH1
BCR-ABL	IDH2

Detection of residual cells and molecules



THERAPY >

TYPICAL SENSITIVITY
1/10,000 to 1/1,000,000

Ultra-deep sequencing
Real-time PCR
Digital PCR
Flow cytometry

Outcome

NEGATIVE

Continued monitoring
Maintenance chemotherapy?

POSITIVE

DISCUSS OPTIONS

Stem cell transplant
Additional chemotherapy
Enrollment in clinical trial